Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience
Authors:
- Miriam LangoMLMiriam Lango
- Sidrah AhmedSASidrah Ahmed
- 10 November 2010
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 33 (10) , 1433-1440
Abstract
Background. Oropharyngeal, laryngeal, and hypopharyngeal cancer treatment has changed at our institution, but survival outcomes have not been evaluated. Methods. We approached the evaluation by a retrospective single-institution cohort study. Results. Review of 180 patient records from 1993 to 2004 revealed that the number of patients with oropharyngeal cancer treated nearly doubled, whereas the number of patients with laryngeal and hypopharyngeal cancers declined (p = .006). Since 2000, concurrent chemotherapeutic regimens rather than radiation alone became the dominant treatment approach, with associated improvements in recurrence-free and overall survival (p = .009 and p = .006, respectively). Stratification by tumor site, however, revealed the survival of patients with oropharyngeal cancer improved markedly, whereas the survival of patients with laryngeal cancer did not change. In the multivariate analysis, T classification (p = .0001) and chemotherapy use (p = .0001) were associated with improved survival. The recurrence-free survival of nonsmokers was better than that for former or current smokers (p = .01), but was accounted for by earlier T classification on presentation in the multivariate analysis (p = .0001). The predominant initial site of failure remained at the primary site for oropharyngeal cancer (14 of 17 relapses or 82%), but not laryngeal cancer (3 of 7 relapses or 42%). As a result, an increasing number of patients with recurrent oropharyngeal cancer, and a decreasing number of recurrent laryngeal cancer patients were evaluated for salvage surgery. Patients with oropharyngeal recurrences, however, were less likely to undergo surgery with curative intent (p = .02) and were less likely to achieve locoregional control after disease recurrence. Conclusions. The survival of patients with oropharyngeal and hypopharyngeal cancers treated at our institution has improved over the last 15 years, which is likely related to changes in treatment and tumor biology. The improvement was not observed in patients with laryngeal cancer. A subset of patients with oropharyngeal cancer remain subject to local failure and disease-related death. © 2010 Wiley Periodicals, Inc. Head Neck 33:1433–1440, 2010Keywords
This publication has 17 references indexed in Scilit:
- Improved Survival in Patients With Stage III-IV Head and Neck Cancer Treated With Radiotherapy as Primary Local Treatment ModalityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy NumberJournal of Clinical Oncology, 2008
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399Journal of Clinical Oncology, 2007
- Trends in head and neck cancer incidence in relation to smoking prevalenceCancer, 2007
- Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and SurvivalThe Laryngoscope, 2006
- Clinical Implications of Human Papillomavirus in Head and Neck CancersJournal of Clinical Oncology, 2006
- Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER databaseInternational Journal of Cancer, 2005
- Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neckHead & Neck, 2003